Literature DB >> 21671905

Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism.

Nicolette C Ross1, Kate J Reilley, Thomas F Murray, Jane V Aldrich, Jay P McLaughlin.   

Abstract

BACKGROUND AND
PURPOSE: The κ opioid receptor antagonists demonstrate potential for maintaining abstinence from psychostimulant abuse, but existing non-peptide κ-receptor selective antagonists show exceptionally long activity. We hypothesized that the L- and D-Trp isomers of CJ-15,208, a natural cyclic tetrapeptide reported to be a κ-receptor antagonist in vitro, would demonstrate short-acting, dose-dependent antagonism in vivo, preventing reinstatement of cocaine-seeking behaviour. EXPERIMENTAL APPROACH: Affinity, selectivity and efficacy of the L-Trp and D-Trp isomers for opioid receptors were assessed in vitro in radioligand and GTPγS binding assays. Opioid receptor agonist and antagonist activities were characterized in vivo following i.c.v. administration with the 55°C warm water tail-withdrawal assay. The D-Trp isomer, which demonstrated primarily κ-receptor selective antagonist activity, was further evaluated for its prevention of stress- and drug-induced reinstatement of extinguished cocaine conditioned place preference (CPP). KEY
RESULTS: The two isomers showed similar affinity and selectivity for κ receptors (K(i)  30-35 nM) as well as κ receptor antagonism in vitro. As expected, the D-Trp cyclic tetrapeptide exhibited minimal agonist activity and induced dose-dependent κ-receptor selective antagonism lasting less than 18 h in vivo. Pretreatment with this peptide prevented stress-, but not cocaine-induced, reinstatement of extinguished cocaine CPP. In contrast, the L-Trp cyclic tetrapeptide unexpectedly demonstrated mixed opioid agonist/antagonist activity. CONCLUSIONS AND IMPLICATIONS: The L-Trp and the D-Trp isomers of CJ-15,208 demonstrate stereospecific opioid activity in vivo. The relatively brief κ opioid receptor antagonism, coupled with the prevention of stress-induced reinstatement of extinguished cocaine-seeking behaviour, suggests the D-Trp isomer could be used therapeutically to maintain abstinence from psychostimulant abuse.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21671905      PMCID: PMC3346240          DOI: 10.1111/j.1476-5381.2011.01544.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  Hydrostatic pressure alters the time course of GTP

Authors: 
Journal:  Biol Bull       Date:  1999-12       Impact factor: 1.818

2.  Bimorphinans as highly selective, potent kappa opioid receptor antagonists.

Authors:  A S Portoghese; A W Lipkowski; A E Takemori
Journal:  J Med Chem       Date:  1987-02       Impact factor: 7.446

3.  Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.

Authors:  J P McLaughlin; K P Hill; Q Jiang; A Sebastian; S Archer; J M Bidlack
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

Review 4.  Nalbuphine.

Authors:  W K Schmidt; S W Tam; G S Shotzberger; D H Smith; R Clark; V G Vernier
Journal:  Drug Alcohol Depend       Date:  1985-02       Impact factor: 4.492

5.  Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men.

Authors:  Nancy K Mello; Jack H Mendelson; Michelle B Sholar; Maria Jaszyna-Gasior; Nathalie Goletiani; Arthur J Siegel
Journal:  Neuropsychopharmacology       Date:  2005-03       Impact factor: 7.853

6.  Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.

Authors:  S Arttamangkul; J E Ishmael; T F Murray; D K Grandy; G E DeLander; B L Kieffer; J V Aldrich
Journal:  J Med Chem       Date:  1997-04-11       Impact factor: 7.446

7.  Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model.

Authors:  F Ivy Carroll; Louis S Harris; Mario D Aceto
Journal:  Eur J Pharmacol       Date:  2005-10-19       Impact factor: 4.432

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Kappa agonist-induced reinstatement of cocaine seeking in squirrel monkeys: a role for opioid and stress-related mechanisms.

Authors:  Glenn R Valdez; Donna M Platt; James K Rowlett; Daniela Rüedi-Bettschen; Roger D Spealman
Journal:  J Pharmacol Exp Ther       Date:  2007-08-16       Impact factor: 4.030

10.  CJ-15,208, a novel kappa opioid receptor antagonist from a fungus, Ctenomyces serratus ATCC15502.

Authors:  Toshiyuki Saito; Hideo Hirai; Yoon-Jeong Kim; Yasuhiro Kojima; Yasue Matsunaga; Hiroyuki Nishida; Tatsuo Sakakibara; Osamu Suga; Tetsujo Sujaku; Nakao Kojima
Journal:  J Antibiot (Tokyo)       Date:  2002-10       Impact factor: 2.649

View more
  21 in total

1.  Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.

Authors:  Jai Shankar K Yadlapalli; Benjamin M Ford; Amit Ketkar; Anqi Wan; Narasimha R Penthala; Robert L Eoff; Paul L Prather; Maxim Dobretsov; Peter A Crooks
Journal:  Pharmacol Res       Date:  2016-09-13       Impact factor: 7.658

2.  Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.

Authors:  Abdulrahman Almatroudi; Stephen M Husbands; Christopher P Bailey; Sarah J Bailey
Journal:  J Psychopharmacol       Date:  2015-06-04       Impact factor: 4.153

3.  Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.

Authors:  Abdulrahman Almatroudi; Mehrnoosh Ostovar; Christopher P Bailey; Stephen M Husbands; Sarah J Bailey
Journal:  Br J Pharmacol       Date:  2017-11-06       Impact factor: 8.739

4.  Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.

Authors:  Archana Mukhopadhyay; Laura E Hanold; Hamsa Thayele Purayil; Solomon A Gisemba; Sanjeewa N Senadheera; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2017-07-10       Impact factor: 4.742

5.  Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208.

Authors:  Jane V Aldrich; Santosh S Kulkarni; Sanjeewa N Senadheera; Nicolette C Ross; Kate J Reilley; Shainnel O Eans; Michelle L Ganno; Thomas F Murray; Jay P McLaughlin
Journal:  ChemMedChem       Date:  2011-07-14       Impact factor: 3.466

6.  Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine-seeking behaviour.

Authors:  Ariana C Brice-Tutt; Lisa L Wilson; Shainnel O Eans; Heather M Stacy; Chloe A Simons; Grant G Simpson; Jeremy S Coleman; Michael J Ferracane; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2020-07-16       Impact factor: 8.739

7.  Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.

Authors:  J V Aldrich; S N Senadheera; N C Ross; K A Reilley; M L Ganno; S E Eans; T F Murray; J P McLaughlin
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

8.  The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.

Authors:  Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin
Journal:  J Nat Prod       Date:  2013-01-17       Impact factor: 4.050

9.  The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.

Authors:  Shainnel O Eans; Michelle L Ganno; Kate J Reilley; Kshitij A Patkar; Sanjeewa N Senadheera; Jane V Aldrich; Jay P McLaughlin
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

10.  A Cyclic Tetrapeptide ("Cyclodal") and Its Mirror-Image Isomer Are Both High-Affinity μ Opioid Receptor Antagonists.

Authors:  Grazyna Weltrowska; Thi M-D Nguyen; Nga N Chung; JodiAnne Wood; Xiaoyu Ma; Jason Guo; Brian C Wilkes; Yang Ge; André Laferrière; Terence J Coderre; Peter W Schiller
Journal:  J Med Chem       Date:  2016-10-03       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.